The division of Nephrology and Hypertension at the Texas Tech University Health Science Center (TTUHSC) El Paso has been invited to collaborate in a multiple-institute, nationwide research consortium that aims to better understand the causes behind, and discover new potential treatments for, lupus nephritis. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease,…
A new and unusual study describes a three- to 32-year follow-up analysis of systemic lupus erythematosus (SLE) patients to understand the number who achieve complete remission (three years) and subsequently remain in remission. The study, titled “Analysis of Complete Remission in Lupus Patients over a period of 32 years,”…
Researchers have identified increased exosomal microRNAs in lupus nephritis patients’ urine, and think it may prove to be a useful, non-invasive disease biomarker. Their paper, titled “Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus Erythematosus,” was published in PLOS One. Systemic lupus erythematosus (SLE), a chronic autoimmune disease,…
Delazatide may be effective to control flares in lupus nephritis patients, according to recent data from The Alliance for Children’s Therapeutics (ACT), a pediatric research collaboration between Seattle Children’s Research Institute and the biotech company Kineta, Inc. The results were presented during the recent American College of Rheumatology Annual Meeting in San Francisco,…
Horizon Pharma announced a partnership with the Alliance for Lupus Research (ALR), a non-governmental national health organization, to study the efficacy and safety of RAYOS (prednisone) delayed-release tablets to manage systemic lupus erythematosus (SLE) therapy. RAYOS, known as LODOTRA in Europe, differs from other prednisone formulations because the pharmacokinetic properties of its formulation allow the delayed…
GlaxoSmithKline (GSK) announced positive results from its BLISS-SC Phase 3 study testing the efficacy of Benlysta (belimumab) in patients with active and autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. The results, detailed in “A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard…
Mallinckrodt Pharmaceuticals has revealed that H.P. Acthar Gel is effective in the treatment of patients with persistently active systemic lupus erythematosus (SLE) who are under corticosteroid therapy, according to recent study results. Though the study’s primary endpoint was not met, the drug led to attenuation of disease activity in participants and met some…
Actress, singer, fashion designer and celebrity Selena Gomez’s revelation that she has been undergoing chemotherapy for lupus is raising the profile of the not well-understood disorder. A Grand Prairie, Texas, native, Gomez, 23, went public about her struggles with lupus recently, explaining to Billboard’s Joe Lynch that her recent…
The Lupus Foundation of America presented two awards recognizing distinguished career achievements in lupus research to Dr Mariana J. Kaplan, of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (NIH), and Dr Timothy B. Niewold, of the Mayo Clinic, at a Nov. 8 foundation ceremony…
A recent study conducted by researchers at the Hospital for Special Surgery evaluated the Patient Reported Outcomes Measurement Information System (PROMIS) in lupus patients, concluding that the survey could also be used to assess subjective patient experiences. Researchers also reported a disconnect between the patient point of view and objective symptoms, emphasizing the need to…